drugset / Trial / NCT00065728

Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

NCT00065728

Phase 3 Terminated 111 enrolled Alcon Research
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.

Timeline

Start
2003-06
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Anecortave Acetate Small molecule 15 mg Other

Indications